| Identification | Back Directory | [Name]
QUININE HYDROBROMIDE | [CAS]
549-49-5 | [Synonyms]
Quinini
bromoquinine
chininhydrobromid
Quinine hydrobromide
quinine,monohydrobromide
6’-methoxy-,monohydrobromide,(8-alpha,9r)-cinchonan-9-o
(6-methoxy-4-quinolyl)-(5-vinylquinuclidin-2-yl)methanol hydrobromide
(5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrobromide
(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol:hydrobromide | [EINECS(EC#)]
208-967-2 | [Molecular Formula]
C20H25BrN2O2 | [MDL Number]
MFCD00198095 | [MOL File]
549-49-5.mol | [Molecular Weight]
405.33 |
| Hazard Information | Back Directory | [Chemical Properties]
yellow prisms | [Uses]
Quinidine hydrobromide is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine hydrobromide is also a K+ channel blocker with an IC50 of 19.9 μM. Quinidine hydrobromide can be used for malaria research[1][2][3]. | [in vivo]
Quinidine hydrobromide is rapidly absorbed, with peak plasma concentrations 60-90 min after an oral dose. Other salts (gluconate, polygalacturonate) are more slowly absorbed, with lower peak concentrations[2].
Quinidine hydrobromide is approximately 70-90 % bound to plasma proteins. It undergoes hepatic oxidative metabolism to form an N-oxide, a 3-hydroxy form, an O-demethyl form and 2'-quinidinone[2].
Quinidine hydrobromide inhibits metabolism of amphetamine in rats. Quinidine hydrobromide pretreatment results in a significant decrease in the excretion of p-hydroxyamphetamine at 24 and 48 h to 7.2 and 24.1% of the vehicle-control levels, respectively, accompanied by a significant increase in amphetamine excretion between 24 and 48 h to 542% of the control[3]. | [References]
[1] Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991 Jul;103(3):1807-13. DOI:10.1111/j.1476-5381.1991.tb09867.x
[2] Roden DM, et al. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. DOI:10.1016/0163-7258(83)90012-8 |
|
|